Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform
Biotricity (OTCQB:BTCY) and B-Secur have announced a significant expansion of their cardiac monitoring platform to include consumer wearables integration. The device-neutral platform, initially launched in early 2025 for ambulatory cardiac monitoring, will now incorporate ECG data from smartwatches, smart rings, and fitness trackers.
The enhanced platform leverages B-Secur's FDA-cleared HeartKey® ECG algorithms to deliver medical-grade accuracy. This advancement enables seamless integration of consumer device data into regulated care pathways, bridging the gap between consumer wearables and clinical care. The initiative aims to address the growing global cardiovascular disease burden, which is projected to triple global costs to $1.8 trillion by 2050.
Biotricity (OTCQB:BTCY) e B‑Secur hanno annunciato un’importante estensione della loro piattaforma di monitoraggio cardiaco per integrare i dispositivi indossabili consumer. La piattaforma device‑neutral, lanciata all’inizio del 2025 per il monitoraggio cardiaco ambulatoriale, includerà ora i dati ECG provenienti da smartwatch, smart ring e fitness tracker.
La piattaforma potenziata sfrutta gli algoritmi HeartKey® ECG di B‑Secur, approvati dalla FDA, per offrire precisione di livello medico. Questo progresso permette di integrare senza soluzione di continuità i dati dei dispositivi consumer nei percorsi di cura regolamentati, colmando il divario tra i wearable commerciali e l’assistenza clinica. L’iniziativa punta a contrastare l’aumento del carico globale delle malattie cardiovascolari, la cui spesa mondiale è prevista triplicare fino a 1,8 trilioni di dollari entro il 2050.
Biotricity (OTCQB:BTCY) y B‑Secur han anunciado una ampliación significativa de su plataforma de monitorización cardíaca para incluir la integración de wearables de consumo. La plataforma independiente de dispositivos, lanzada a principios de 2025 para el monitoreo cardíaco ambulatorio, incorporará ahora datos ECG procedentes de relojes inteligentes, anillos inteligentes y pulseras de actividad.
La plataforma mejorada aprovecha los algoritmos HeartKey® ECG de B‑Secur, autorizados por la FDA, para ofrecer precisión de grado médico. Este avance permite integrar sin fricciones los datos de los dispositivos de consumo en vías de atención reguladas, cerrando la brecha entre los wearables comerciales y la atención clínica. La iniciativa busca hacer frente al creciente peso mundial de las enfermedades cardiovasculares, cuyo coste global se prevé que se triplique hasta 1,8 billones de dólares para 2050.
Biotricity (OTCQB:BTCY)와 B‑Secur은 소비자용 웨어러블 통합을 포함하도록 심장 모니터링 플랫폼을 크게 확장한다고 발표했습니다. 조기 2025년에 외래 심장 모니터링용으로 출시된 기기 중립 플랫폼은 이제 스마트워치, 스마트링, 피트니스 트래커의 심전도(ECG) 데이터를 통합합니다.
강화된 플랫폼은 B‑Secur의 FDA 승인 HeartKey® ECG 알고리즘을 활용해 의료 수준의 정확도를 제공합니다. 이 발전으로 소비자 기기 데이터를 규제된 진료 경로에 원활하게 통합할 수 있어 상업용 웨어러블과 임상 진료 간의 격차를 메웁니다. 이 이니셔티브는 2050년까지 전 세계 비용이 1.8조 달러로 세 배로 증가할 것으로 예상되는 심혈관 질환의 증가하는 부담에 대응하는 것을 목표로 합니다.
Biotricity (OTCQB:BTCY) et B‑Secur ont annoncé une extension significative de leur plateforme de surveillance cardiaque pour intégrer les wearables grand public. La plateforme neutre vis‑à‑vis des appareils, lancée début 2025 pour la surveillance cardiaque ambulatoire, incorporera désormais les données ECG provenant de montres connectées, bagues intelligentes et trackers d’activité.
La plateforme améliorée exploite les algorithmes HeartKey® ECG de B‑Secur, approuvés par la FDA, pour offrir une précision de qualité médicale. Cette avancée permet l’intégration fluide des données des appareils grand public dans des parcours de soins réglementés, comblant ainsi le fossé entre les wearables et la prise en charge clinique. L’initiative vise à répondre au fardeau croissant des maladies cardiovasculaires dans le monde, dont les coûts mondiaux devraient tripler pour atteindre 1,8 billion de dollars d’ici 2050.
Biotricity (OTCQB:BTCY) und B‑Secur haben eine wesentliche Erweiterung ihrer kardiologischen Überwachungsplattform angekündigt, die nun auch die Integration von Consumer‑Wearables umfasst. Die geräteunabhängige Plattform, die Anfang 2025 für ambulante Herzüberwachung eingeführt wurde, wird künftig ECG‑Daten von Smartwatches, Smart‑Ringen und Fitness‑Trackern einbinden.
Die erweiterte Plattform nutzt die FDA‑zugelassenen HeartKey® ECG‑Algorithmen von B‑Secur, um medizinische Genauigkeit zu liefern. Dieser Fortschritt ermöglicht die nahtlose Integration von Daten aus Verbrauchergeräten in regulierte Versorgungswege und überbrückt die Lücke zwischen Wearables für Endverbraucher und klinischer Versorgung. Das Vorhaben zielt darauf ab, der wachsenden globalen Belastung durch Herz‑Kreislauf‑Erkrankungen entgegenzuwirken, deren weltweite Kosten bis 2050 voraussichtlich auf 1,8 Billionen US‑Dollar ansteigen werden.
- Integration of consumer wearables data into clinical-grade cardiac monitoring platform
- Platform leverages FDA-cleared HeartKey® ECG algorithms for medical-grade accuracy
- Device-agnostic design allows seamless integration with various smart devices
- Addresses growing global demand for preventive cardiovascular solutions
- Operating in highly competitive consumer wearables market
- Faces challenge of scaling amid projected triple increase in global cardiovascular costs
Insights
Biotricity and B-Secur's expansion into consumer wearables creates a significant market opportunity, bridging consumer health data with clinical workflows.
Biotricity and B-Secur are making a strategic move by expanding their joint cardiac monitoring platform to support ECG data from consumer wearables. This creates a powerful bridge between consumer health devices and clinical care pathways - a critical gap in the current digital health ecosystem.
The platform's device-agnostic design is particularly noteworthy, as it allows integration of data from various consumer devices (smartwatches, rings, fitness trackers) into Biotricity's medical workflow. This interoperability addresses one of healthcare's biggest challenges: fragmented data systems.
What makes this development technically significant is the integration of B-Secur's FDA-cleared HeartKey® ECG algorithms, which brings clinical-grade accuracy to consumer device data. This solves the trust problem many physicians have with consumer-generated health data.
From a market perspective, the timing is strategic. The global cardiovascular disease burden is projected to triple costs to
For Biotricity (OTCQB:BTCY), this expansion represents potential for recurring revenue streams through cloud-based services while extending their reach beyond traditional medical devices into the much larger consumer health market. The cloud infrastructure suggests a scalable SaaS model that could yield higher margins than hardware-only offerings.
REDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solutions, and B-Secur, a leader in ECG algorithm and biosensing technology, are transforming the consumer wearables market with an enhancement to their joint cardiac monitoring platform.
The device-neutral platform, which launched in early 2025 for ambulatory cardiac monitoring, will now support ECG data from consumer wearables. This advancement enables the seamless integration and review of user data collected from smartwatches, smart rings, fitness trackers, and other mobile health products within Biotricity’s cloud-based medical workflow.
The move solidifies Biotricity and B-Secur’s leadership in digital cardiovascular innovation, positioning the companies at the forefront of the rapidly expanding heart health market.
“Biotricity’s mission has been to make high-quality cardiac care accessible to everyone,” explained Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. “Through our strategic collaboration with B-Secur, we’re introducing clinical-grade heart monitoring to consumer wearables, providing patients and their healthcare providers with the tools they need to understand and manage heart health like never before.”
Leveraging B-Secur’s FDA-cleared HeartKey® ECG algorithms and advanced analytics, the platform delivers medical-grade accuracy trusted by healthcare professionals. Its device-agnostic design and cloud-enabled infrastructure allow developers and OEMs to seamlessly integrate data from smart devices into regulated care pathways, efficiently bridging the gap between consumer devices and clinical care.
“This advancement addresses the growing global demand for preventive cardiovascular solutions in younger and aging populations,” said Tyeler Dean, VP of Medical at B-Secur. “It enables scalable, user-friendly health tech while maintaining the same level of clinical-grade accuracy trusted by healthcare professionals and increasingly expected by consumers.”
Cardiovascular disease, responsible for 1 in 3 deaths worldwide, is projected to triple global costs to
About B-Secur
B-Secur is an advanced biosensing technology company on a mission to set a new level of care in health monitoring through development of both on-device and cloud applications, driving preventative and proactive fitness and health management. B-Secur's signal processing provides medical-grade ECG data for faster, more confident diagnosis, treatment, and management. B-Secur is ISO 13485:2016 certified.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Contacts:
Corinna Keenan
B-Secur
Corinna.keenan@b-secur.com
###ENDS###
FAQ
What is the new feature announced by Biotricity (BTCY) for their cardiac monitoring platform?
How does Biotricity's expanded platform benefit healthcare providers?
What technology is Biotricity using for ECG monitoring in consumer devices?
What is the market opportunity for Biotricity's cardiovascular monitoring solution?
When did Biotricity initially launch their cardiac monitoring platform?
